by April Breyer Menon | May 23, 2019
Venable partner Ha Kung Wong spoke at the ISPOR 2019 annual meeting as part of a panel that reviewed the current state of the biosimilar market and challenges to biosimilar uptake in the U.S. His comments on pending Congressional action relating to the Purple Book,...
by April Breyer Menon | May 7, 2019
Download PDF Download...
by April Breyer Menon | Apr 5, 2019
Download PDF Download...
by April Breyer Menon | Mar 27, 2019
Ha Kung Wong comments on what could happen if the Trump administration is successful in persuading the Fifth Circuit Court of Appeals to affirm a lower court ruling that the Affordable Care Act is invalid for the Center for Biosimilars. View Full Article at the Center...
by April Breyer Menon | Mar 19, 2019
While the biosimilar market in the U.S. has gotten off to a relatively slow start compared to Europe, where biosimilars have been available since 2006, it has recently gained momentum and will continue to grow in the coming years as more “blockbuster” biologics lose...